Bristol-Myers Squibb has agreed to co-develop Exelixis' XL413, an investigational cancer treatment that works by turning off Cdc7, which is said to prevent cell death in tumor cells. Exelixis will get $20 million in milestone fees from Bristol-Myers as part of the partnership, which began in January 2007.

Related Summaries